卖什么
Regulating the immune system to block cancer & autoimmune diseases
商业模式拆解
买家：谁掌握预算？
未核实Pharma licensees/investors; eventual payers and prescribers if approved.
工作流：什么输入变成什么输出？
Lead program SFA-002 is an oral, once-daily deuterated short-chain fatty acid that resets immunity via the gut-immune axis; Phase 1b in 28 plaque psoriasis patients over 12 weeks, Phase 2 in preparation.
经济账：省了什么，怎么收费？
未核实Clinical-stage biotech with no product revenue; value rests on Phase 1b data (no treatment-emergent adverse events, 18 granted patents) and future licensing/partnering or approval.
渠道：怎么接触到客户？
Investor and business inquiries by email; site directed at investors, healthcare professionals and the public.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2021 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.